Stocks Health care MGTX
NASDAQ · Health careMeiraGTx Holdings plc (MGTX)
MeiraGTx Holdings plc brought in $397.5M of revenue over the twelve months to June 30, 2026, up 948.3% from a year earlier. Net income was $79M, a net margin of 19.9%. In fiscal 2025 capital spending exceeded operating cash flow by $50.2M. At June 30, 2026 it held $143.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about MeiraGTx Holdings plc
- Net worth
- MeiraGTx Holdings plc has a market value (market cap) of $923.9M at the latest share price, and shareholders' equity of $215.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $81.4M (+144.6% year on year), with a net loss of $114.2M. Over the 12 months to June 30, 2026: revenue $397.5M, net income $79M.
- Cash flow
- In fiscal 2025 operations used $46.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- MeiraGTx Holdings plc's next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What MeiraGTx Holdings plc does
MeiraGTx Holdings plc is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker MGTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $81.4M | -$114.2M | -$1.42 | -$50.2M |
| 2024 | $33.3M | -$147.8M | -$2.12 | -$109.5M |
| 2023 | $14M | -$84M | -$1.49 | -$125.5M |
| 2021 | $15.9M | -$129.6M | -$2.87 | -$118.1M |
| 2021 | $37.7M | -$79.6M | -$1.80 | -$56.9M |
| 2020 | $15.6M | -$58M | -$1.54 | -$84.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where MGTX ranks in Health care
Latest SEC filings
What MeiraGTx Holdings plc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 23, 2026Executive or director change8-KMeiraGTx appointed Alan M. Sebulsky to its Board of Directors as a Class I director.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 8,609% to $321.4M versus the same quarter last year; diluted EPS $1.71 versus -$0.48.
- August 13, 2026
- July 7, 2026
- June 15, 2026
- May 14, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 85% to $293K versus the same quarter last year; diluted EPS -$0.57 versus -$0.51.
- May 14, 2026
- May 13, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running MeiraGTx Holdings plc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $1.7M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 20, 2026 | Giroux RichardCFO & COO | Soldpre-planned (10b5-1) | 56,000 | $557.2K |
| October 6, 2026 | Naylor StuartCHIEF SCI OFCR, OPHTHALMOLOGY | Soldpre-planned (10b5-1) | 27,659 | $294.3K |
| August 18, 2026 | Forbes AlexandriaPRESIDENT & CEO, Director | Soldpre-planned (10b5-1) | 62,000 | $859.3K |
| July 21, 2026 | Giroux RichardCFO & COO | Soldpre-planned (10b5-1) | 56,000 | $700.6K |
| July 7, 2026 | Naylor StuartCHIEF SCI OFCR, OPHTHALMOLOGY | Soldpre-planned (10b5-1) | 2,547 | $35.3K |
| July 7, 2026 | Naylor StuartCHIEF SCI OFCR, OPHTHALMOLOGY | Soldpre-planned (10b5-1) | 25,112 | $374.2K |
| June 10, 2026 | Harris Keith R.Director | Exercised options | 75,000 | - |
| May 27, 2026 | Giroux RichardCFO & COO | Gave as a gift | 7,000 | - |
Who owns MGTX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Perceptive Advisors LLC13D, may seek influence with 2 related filers | 12.6% | April 24, 2026 |
| Rubric Capital Management LP13G, passive with 1 related filers | 9.83% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 157 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Sanofi | 12,197,737 | 0 |
| Perceptive Advisors LLC | 10,786,658 | +460,555 |
| Rubric Capital Management LP | 9,100,000 | +2,100,000 |
| Johnson & Johnson | 6,641,064 | 0 |
| BlackRock, Inc. | 4,757,178 | +1,589,030 |
| Adage Capital Partners GP, L.L.C. | 4,400,000 | +400,000 |
| Opaleye Management Inc. | 3,550,000 | +1,426,741 |
| Millennium Management LLC | 2,971,752 | -493,947 |
| 683 Capital Management, LLC | 2,300,000 | -150,000 |
| Woodline Partners LP | 1,500,135 | +1,199,812 |
| State Street Corp | 1,393,222 | +639,844 |
| Morgan Stanley | 1,312,703 | -277,237 |
| Knoll Capital Management, LLC | 1,250,000 | 0 |
| Kennedy Capital Management LLC | 1,105,421 | +247,042 |
| Long Focus Capital Management, LLC | 1,080,300 | +555,555 |
| Jacobs Levy Equity Management, Inc | 1,015,106 | +1,001,433 |
| D. E. Shaw & Co., Inc. | 852,902 | +427,621 |
| Heights Capital Management, Inc | 850,000 | new |
| Geode Capital Management, LLC | 849,082 | +264,183 |
| Vanguard Portfolio Management LLC | 723,563 | +326,282 |
Insiders
7 insiders reported holding 14,008,335 shares in total, about $134.8M at the last price.
| Holder | Shares |
|---|---|
| Perceptive Advisors LLCDirector, 10% owner | 10,786,65810,786,658 held indirectly |
| Forbes AlexandriaPRESIDENT & CEO, Director | 1,325,695 |
| Giroux RichardCFO & COO | 852,530 |
| Naylor StuartCHIEF SCI OFCR, OPHTHALMOLOGY | 613,187 |
| Harris Keith R.Director | 200,000 |
| Zeldin Robert KCHIEF MEDICAL OFFICER | 172,888 |
| Wollin Robert JGENERAL COUNSEL AND SECRETARY | 57,377 |
Questions about MGTX
What does MeiraGTx Holdings plc do?
MeiraGTx Holdings plc is a company in the Health care sector, listed on NASDAQ as MGTX. Its shares trade on NASDAQ under the ticker MGTX.
What is MeiraGTx Holdings plc's net worth?
MeiraGTx Holdings plc has a market value (market cap) of $923.9M at the latest share price, and shareholders' equity of $215.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is MeiraGTx Holdings plc profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $79M on revenue of $397.5M, a net margin of 19.9%.
How much revenue does MeiraGTx Holdings plc make?
Over the twelve months to June 30, 2026 MeiraGTx Holdings plc reported revenue of $397.5M. That is 948.3% more than a year earlier.
When did MeiraGTx Holdings plc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 20, 2026.
When is MeiraGTx Holdings plc's next earnings report?
MeiraGTx Holdings plc's next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare MGTX with
Follow MGTX
Get an email when MeiraGTx Holdings plc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values MeiraGTx Holdings plc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.